0001752724-23-276832.txt : 20231212 0001752724-23-276832.hdr.sgml : 20231212 20231212104858 ACCESSION NUMBER: 0001752724-23-276832 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231212 DATE AS OF CHANGE: 20231212 EFFECTIVENESS DATE: 20231212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: abrdn Healthcare Investors CENTRAL INDEX KEY: 0000805267 IRS NUMBER: 046564285 STATE OF INCORPORATION: PA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-04889 FILM NUMBER: 231480308 BUSINESS ADDRESS: STREET 1: 1900 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 6177728515 MAIL ADDRESS: STREET 1: 1900 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19103 FORMER COMPANY: FORMER CONFORMED NAME: TEKLA HEALTHCARE INVESTORS DATE OF NAME CHANGE: 20141015 FORMER COMPANY: FORMER CONFORMED NAME: H&Q HEALTHCARE INVESTORS DATE OF NAME CHANGE: 19920703 N-CEN 1 primary_doc.xml X0404 N-CEN LIVE 0000805267 XXXXXXXX 811-04889 false false false N-2 abrdn Healthcare Investors 811-04889 0000805267 549300SNASESIFOS6V75 100 FEDERAL STREET, 19TH FLOOR BOSTON 02110 US-MA US 617-772-8500 State Street Bank and Trust Company 1 Congress Street Suite 1 Boston 02114 617-786-3000 Accounting and Custody Records Tekla Capital Management LLC 100 Federal Street 19th Floor Boston 02110 617-772-8500 Fund Administration Records N N N-2 N Thomas M. Kent, CPA N/A N Rakesh K. Jain, Ph.D. N/A N W. Mark Watson, CPA N/A N Daniel R. Omstead, Ph.D. N/A Y Jeffrey A. Bailey N/A N Kathleen L. Goetz N/A N Laura Woodward, CPA N/A 100 Federal Street, 19th Floor Boston 02110 XXXXXX N N N N N N KPMG LLP 185 5493003PVCIGA21K0K42 Y N N N N abrdn Healthcare Investors 549300SNASESIFOS6V75 N 0 0 0 N/A Y N Y N N Goldman Sachs Bank USA KD3XUN7C6T14HNAYLU02 N N Revenue sharing split Cash collateral reinvestment fee 7817965.20000000 94792.00000000 Rule 18f-4 (17 CFR 270.18f-4) Rule 18f-4(e) (17 CFR 270.18f-4(e)) Rule 17a-6 (17 CFR 270.17a-6) N N N N Tekla Capital Management LLC 801-61018 000119626 254900YSXGYL9SE8C952 N Computershare Trust Company, National Association 85-11340 2549001YYB62BVMSAO13 N N N ICE Data Services, Inc. 13-3668779 Tax ID N Refinitiv US Holdings Inc. 549300NF240HXJO7N016 N N UBS Switzerland AG 549300WOIFUSNYH0FL22 CH N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) BNP Paribas R0MUWSFPU8MPRO8K5P83 FR N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Clearstream Banking S.A. 549300OL514RA0SXJJ44 LU N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) State Street Bank and Trust Company (Boston, MA, US, Branch) 571474TGEMMWANRLN572 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) State Street Bank and Trust Company (Edinburgh, GB, Branch) 571474TGEMMWANRLN572 GB N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) N Computershare Trust Company, National Association 2549001YYB62BVMSAO13 N N N State Street Bank and Trust Company (Boston, MA, US, Branch) 571474TGEMMWANRLN572 N N N UBS Securities LLC 8-22651 000007654 T6FIZBDPKLYJKFCRVK44 8292.72000000 BNY Mellon Capital Markets, LLC 8-35255 000017454 VJW2DOOHGDT6PR0ZRO63 63713.16000000 Mizuho Securities USA LLC 8-37710 000019647 7TK5RJIZDFROZCA6XF66 10429.95000000 National Financial Services LLC 8-26740 000013041 549300JRHF1MHHWUAW04 31492.47000000 Sanford C. Bernstein & Co., LLC 8-52942 000104474 549300I7JYZHT7D5CO04 4794.57000000 Wells Fargo Securities, LLC 8-65876 000126292 VYVVCKR63DVZZN70PB21 9288.87000000 Nomura Securities International, Inc. 8-15255 000004297 OXTKY6Q8X53C9ILVV871 9099.69000000 Jefferies LLC 8-15074 000002347 58PU97L1C0WSRCWADL48 7801.86000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 59823.93000000 Stifel, Nicolaus & Company, Incorporated 8-1447 000000793 5WUVMA08EYG4KEUPW589 14655.99000000 234348.00000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 240779840.16000000 European Biotech Acquisition Corp. N/A N/A 984500Y57CDE4CE7CC20 NL 785400.00000000 State Street Bank and Trust Company N/A N/A 571474TGEMMWANRLN572 7517947000.00000000 Hibercell Inc. N/A N/A N/A 708965.40000000 ReCode Therapeutics, Inc. N/A N/A N/A 226665.83000000 AMOLYT PHARMA N/A N/A N/A 3757727.29000000 Arkuda Therapeutics, Inc. N/A N/A N/A MA 984526.69000000 Abcuro, Inc. N/A N/A N/A 1462500.00000000 CuraSen Therapeutics, Inc. N/A N/A N/A 1160644.31000000 Incendia Therapeutics, Inc. N/A N/A N/A 1307688.39000000 7776263491.07000000 N 972575599.68000000 Common stock Tekla Healthcare Investors N N N N N N 0.99000000 1.18000000 15.55000000 18.84000000 true INTERNAL CONTROL RPT 2 NCEN_811-04889_37858811_0923.htm healthcareinvestorsncen.htm - Generated by SEC Publisher for SEC Filing

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Trustees
abrdn Healthcare Investors:

In planning and performing our audit of the financial statements of abrdn Healthcare Investors (formerly, Tekla Healthcare Investors) (the Fund) as of and for the year ended September 30, 2023, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Fund's internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion.

Management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Fund's internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the Public Company Accounting Oversight Board (United States). However, we noted no deficiencies in the Fund's internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of September 30, 2023.

This report is intended solely for the information and use of the management and the Board of Trustees of abrdn Healthcare Investors (formerly, Tekla Healthcare Investors) and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.


 

 

 

/s/ KPMG LLP

 

 

 

Philadelphia, Pennsylvania
November 29, 2023